Cargando…

Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat

BACKGROUND: The antiviral drug molnupiravir is an orally bioavailable prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC), which is used to treat coronavirus disease 2019 (COVID-19). However, there is very little information on the barrier distribution of molnupiravir. Our hypothesis is th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Chun-Hao, Peng, Wen-Ya, Lee, Wan-Hsin, Yang, Ling, Lin, Tung-Yi, Yang, Muh-Hwa, Tsai, Tung-Hu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587300/ https://www.ncbi.nlm.nih.gov/pubmed/37857815 http://dx.doi.org/10.1038/s43856-023-00383-w

Ejemplares similares

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier
por: Chang, Chun-Hao, et al.
Publicado: (2023)

Oxidative DNA Damage by N(4)-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir
por: Kobayashi, Hatasu, et al.
Publicado: (2022)

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
por: Clark, Nicole F., et al.
Publicado: (2022)

Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101
por: Chang, Chun-Hao, et al.
Publicado: (2023)

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
por: Stegmann, Kim M., et al.
Publicado: (2022)

The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva
por: Amara, Alieu, et al.
Publicado: (2021)

Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma
por: Komarov, Timofey, et al.
Publicado: (2023)

N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
por: Zibat, Arne, et al.
Publicado: (2023)

Development and validation of assays for the quantification of β-D-N(4)-hydroxycytidine in human plasma and β-D-N(4)-hydroxycytidine-triphosphate in peripheral blood mononuclear cell lysates
por: Parsons, Teresa L., et al.
Publicado: (2021)

Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: FitzGerald, Richard, et al.
Publicado: (2022)

Analysis of the Potential for N(4)-Hydroxycytidine To Inhibit Mitochondrial Replication and Function
por: Sticher, Zachary M., et al.
Publicado: (2020)

Small-Molecule Antiviral β-d-N(4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
por: Agostini, Maria L., et al.
Publicado: (2019)

Significant Inhibition of Porcine Epidemic Diarrhea Virus In Vitro by Remdesivir, Its Parent Nucleoside and β-d-N(4)-hydroxycytidine
por: Xie, Yuanchao, et al.
Publicado: (2021)

β-d-N(4)-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
por: Zhou, Shuntai, et al.
Publicado: (2021)

The effect of molnupiravir on post-acute outcome of COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N(4)-hydroxycytidine (NHC) and a 3′-fluoro-substituted analogue of NHC
por: Wen, Zhao-Hui, et al.
Publicado: (2023)

Synthesis and biological evaluation of new β-D-N(4)-hydroxycytidine analogs against SARS-CoV-2, influenza viruses and DENV-2
por: An, Yeon Jin, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats
por: Yang, Ling, et al.
Publicado: (2022)

Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir
por: Jemth, Ann-Sofie, et al.
Publicado: (2022)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

White targeted chromatographic screening method of Molnupiravir and its metabolite with degradation kinetics characterization and in-silico toxicity
por: Aboras, Sara I., et al.
Publicado: (2023)

Synthesis, base pairing properties and trans-lesion synthesis by reverse transcriptases of oligoribonucleotides containing the oxidatively damaged base 5-hydroxycytidine
por: Küpfer, Pascal A., et al.
Publicado: (2011)

Publisher Correction: Molnupiravir: coding for catastrophe
por: Malone, Brandon, et al.
Publicado: (2021)

Molnupiravir, une affaire franco-européenne
por: Manus, Jean-Marie
Publicado: (2021)

Molnupiravir: From Hope to Epic Fail?
por: Focosi, Daniele
Publicado: (2022)

Why Molnupiravir Fails in Hospitalized Patients
por: Brown, Ashley N., et al.
Publicado: (2022)

In vitro and in vivo efficacy of Molnupiravir against Zika virus infections
por: Wang, Zhuang, et al.
Publicado: (2023)

Body mass index and cholesterol level predict surgical outcome in patients with hepatocellular carcinoma in Taiwan - a cohort study
por: Lee, Ya-Ling, et al.
Publicado: (2016)

153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
por: Strizki, Julie, et al.
Publicado: (2022)

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
por: Huang, Zi-Xin, et al.
Publicado: (2023)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Molnupiravir; molecular and functional descriptors of mitochondrial safety
por: Wallace, K.B., et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Concise two-step chemical synthesis of molnupiravir
por: Pereira, Vinícius R. D., et al.
Publicado: (2022)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mt0gi6mvonurocbafmifu2e3fu